Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MNOV

Medicinova Inc

Dec 26 • 12:07PM ET

1.97

Dollar change -0.10
Percentage change -4.83	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX MRK GILD AMGN BIIB REGN BMY INCY ACAD NBIX

| Held by: VXF IWC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	5.24%	Shs Outstand	49.05M	Perf Week	-8.37%
Market Cap	96.63M	Forward P/E	-	EPS next Y	-0.37	Insider Trans	0.00%	Shs Float	46.48M	Perf Month	-3.90%
Income	-10.29M	PEG	-	EPS next Q	-0.06	Inst Own	19.01%	Short Float	0.74%	Perf Quarter	4.23%
Sales	0.00M	P/S	-	EPS this Y	-29.41%	Inst Trans	2.96%	Short Ratio	4.88	Perf Half Y	36.81%
Book/sh	1.12	P/B	1.75	EPS next Y	-68.18%	ROA	-16.31%	Short Interest	0.35M	Perf Year	42.75%
Cash/sh	0.86	P/C	2.29	EPS next 5Y	20.00%	ROE	-17.19%	52W Range	1.12 - 2.55	Perf YTD	31.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.30%	ROI	-18.61%	52W High	-22.75%	Beta	0.85
Dividend TTM	-	Quick Ratio	16.66	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	75.89%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	16.66	EPS Y/Y TTM	-8.20%	Oper. Margin	-	RSI (14)	42.54	Volatility	4.79% 5.05%
Employees	13	Debt/Eq	0.01	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	9.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-295.92%	Payout	-	Rel Volume	0.89	Prev Close	2.07
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-100.00%	Earnings	Nov 13 AMC	Avg Volume	70.87K	Price	1.97
SMA20	-9.36%	SMA50	1.09%	SMA200	23.86%	Trades		Volume	27,358	Change	-4.83%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-21	Initiated	Maxim Group	Buy	$15
Mar-25-19	Resumed	B. Riley FBR	Buy	$22
Mar-28-18	Initiated	B. Riley FBR, Inc.	Buy	$22
Apr-18-17	Initiated	Credit Suisse	Outperform
Jan-04-13	Reiterated	Ladenburg Thalmann	Buy	$10.50 → $6
May-24-12	Downgrade	MLV & Co	Buy → Hold
Oct-18-11	Reiterated	MLV Capital	Buy	$13 → $6
Jun-22-11	Initiated	Global Hunter Securities	Buy	$4
May-12-10	Initiated	Wedbush	Outperform	$13
Nov-12-08	Reiterated	Ladenburg Thalmann	Buy	$22 → $6
May-15-08	Initiated	Rodman & Renshaw	Mkt Outperform	$9
Jul-09-07	Initiated	Punk, Ziegel & Co	Buy	$22

Show Previous Ratings

Dec-05-24 06:00PM	MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-19-24 09:00AM	MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders (GlobeNewswire) +5.56%
Nov-14-24 06:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver (GlobeNewswire) -8.75%
Nov-13-24 05:08PM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance) -12.28%
Nov-11-24 06:00PM	MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis (GlobeNewswire) +49.02%
07:00PM	Loading…
Oct-23-24 07:00PM	MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) (GlobeNewswire)
Sep-30-24 09:00AM	MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +9.95%
Sep-09-24 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND (GlobeNewswire) -9.05%
Sep-03-24 07:00PM	MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting (GlobeNewswire) +10.00% +7.27%
Aug-29-24 07:00PM	MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition (GlobeNewswire) +14.50%
Jun-20-24 06:00AM	MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations (GlobeNewswire)
Jun-05-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer (GlobeNewswire)
Jun-03-24 06:00AM	MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire) +8.09%
May-28-24 06:00AM	MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions (GlobeNewswire)
May-20-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer (GlobeNewswire)
06:00AM	Loading…
May-14-24 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome (GlobeNewswire)
May-10-24 08:52AM	MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024 (InvestorPlace)
May-09-24 07:45PM	MediciNova: Q1 Earnings Snapshot (Associated Press Finance) +8.15%
May-07-24 06:00AM	MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) (GlobeNewswire)
Apr-02-24 07:00PM	MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) (GlobeNewswire)
Mar-26-24 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan (GlobeNewswire) +8.09%
Mar-20-24 07:00PM	MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society (GlobeNewswire)
Mar-12-24 06:30AM	MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Jan-17-24 06:00AM	MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China (GlobeNewswire)
Dec-21-23 06:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology (GlobeNewswire)
Dec-06-23 06:00PM	MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe (GlobeNewswire)
Nov-19-23 06:00PM	MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
Nov-10-23 09:57AM	MediciNova: Q3 Earnings Snapshot (Associated Press Finance)
Oct-27-23 01:00AM	MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria (GlobeNewswire)
Oct-10-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada (GlobeNewswire)
07:00PM	Loading…
Oct-04-23 07:00PM	MediciNova Receives Gene Therapy Milestone Payment (GlobeNewswire)
Sep-29-23 09:11AM	MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model (Zacks)
Sep-27-23 07:00PM	MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Aug-21-23 08:00AM	MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury (Zacks)
Aug-17-23 07:00PM	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire) -6.63%
Aug-16-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe (GlobeNewswire) +6.93%
Aug-15-23 07:00PM	MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe (GlobeNewswire)
Aug-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe (GlobeNewswire)
Aug-10-23 02:12PM	MediciNova: Q2 Earnings Snapshot (AP Finance)
Jul-23-23 09:56AM	With 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investors (Simply Wall St.)
Jun-29-23 06:00AM	MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting (GlobeNewswire)
May-30-23 05:00AM	MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech (Zacks Small Cap Research)
May-14-23 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe (GlobeNewswire)
May-12-23 07:47PM	MediciNova: Q1 Earnings Snapshot (AP Finance)
Apr-30-23 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada (GlobeNewswire)
Mar-22-23 11:19AM	We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-09-23 06:00PM	MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Feb-27-23 04:57AM	MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled (Zacks Small Cap Research)
Feb-20-23 06:00PM	MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics (GlobeNewswire)
Feb-08-23 06:00PM	MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID (GlobeNewswire)
Jan-30-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder (GlobeNewswire)
Jan-12-23 06:00PM	MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma (GlobeNewswire)
Jan-10-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada (GlobeNewswire)
Jan-09-23 10:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil (GlobeNewswire)
Jan-05-23 06:00PM	MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast) (GlobeNewswire) +6.22%
Dec-06-22 06:00PM	MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation (GlobeNewswire)
Dec-05-22 06:00PM	MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse (GlobeNewswire)
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey) -5.26%
Nov-18-22 05:40AM	MNOV: Well Financed to Get Through Tough Market Conditions (Zacks Small Cap Research)
Oct-13-22 10:50AM	We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-15-22 07:00PM	MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-14-22 07:00PM	MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma (GlobeNewswire)
09:03AM	MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates (Benzinga)
Sep-13-22 07:00PM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada (GlobeNewswire)
Aug-19-22 06:23AM	MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway (Zacks Small Cap Research) -5.00%
Aug-16-22 06:30AM	MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID (GlobeNewswire)
Aug-09-22 07:00PM	MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation (GlobeNewswire)
Jul-27-22 06:30AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea (GlobeNewswire)
Jul-26-22 06:30AM	MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia (GlobeNewswire)
Jul-21-22 07:00PM	MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) (GlobeNewswire)
Jun-29-22 07:00PM	MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury (GlobeNewswire)
Jun-22-22 07:00PM	MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan (GlobeNewswire)
Jun-13-22 06:35AM	MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome (Zacks Small Cap Research)
Jun-08-22 09:05AM	MediciNova Posts Promising Data From COVID-19 Treatment Candidate (Benzinga) +8.94%
06:30AM	MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome (GlobeNewswire)
May-25-22 06:10AM	MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia (Zacks Small Cap Research)
May-06-22 09:48AM	We're Not Very Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Rate (Simply Wall St.)
Apr-21-22 07:00PM	MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference (GlobeNewswire)
Apr-20-22 07:00PM	MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research (GlobeNewswire)
Apr-12-22 11:00PM	MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome (GlobeNewswire)
Apr-11-22 06:30AM	MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia (GlobeNewswire)
Apr-08-22 09:38AM	MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking (Benzinga)
Apr-07-22 07:00PM	MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research (GlobeNewswire)
Apr-06-22 11:15AM	MNOV: Genzyme Patent Litigation Could Lead to Significant Payout (Zacks Small Cap Research)
Mar-17-22 06:30AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea (GlobeNewswire)
Mar-15-22 06:30AM	MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest (GlobeNewswire)
Mar-01-22 05:20AM	MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy (Zacks Small Cap Research)
Feb-28-22 06:30AM	MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal (GlobeNewswire)
Feb-22-22 06:30AM	MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs (GlobeNewswire)
Feb-14-22 01:12PM	The past three years for MediciNova (NASDAQ:MNOV) investors has not been profitable (Simply Wall St.)
Feb-01-22 06:30AM	MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea (GlobeNewswire)
Jan-31-22 06:30AM	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada (GlobeNewswire) +6.61%
Jan-27-22 06:30AM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe (GlobeNewswire) -5.06%
Jan-26-22 06:30AM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe (GlobeNewswire)
Dec-13-21 06:30AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS (GlobeNewswire)
Dec-10-21 06:30AM	MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND (GlobeNewswire)
Nov-23-21 05:04AM	MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model (Zacks Small Cap Research) +43.97%
Nov-22-21 06:30AM	MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
Nov-15-21 12:40PM	We Think MediciNova (NASDAQ:MNOV) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Nov-11-21 06:00PM	MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (GlobeNewswire)

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNOV

Medicinova Inc

Upgrade your FINVIZ experience